Nimbus will apply its computational chemistry and structure-based drug design to a discovery programme in obesity treatment.

According to Citi analysts, Amgen’s acquisition of Dark Blue could further drive the strength of Amgen’s early oncology ...

Cellenkos has received orphan drug designation from the US FDA for its investigational CK0804 Treg therapy to treat ...

Zai Lab has received approval from China’s NMPA for the sNDA for Augtyro to treat adult patients with solid tumours ...

The CDC now recommends 11 vaccines for routine administration in childhood, which it says better allows for “flexibility and ...

Takeda and Protagonist Therapeutics have jointly submitted a NDA seeking approval from the US FDA for rusfertide to treat ...

According to the registration form, Aktis intends to use a large portion of the IPO proceeds on the two programmes. Around ...

Arrowhead Pharmaceuticals has received authorisation from Health Canada for its siRNA medicine, Redemplo, for adults with FCS ...

Reporter Ross Law and editors Abigail Beaney and Robert Barrie reflect on a busy 2025, along with discusing forecasts for ...

Sanofi's $2.56bn bispecific autoimmune deal with Earendil Labs is the second in recent history, and will bolster the French ...

Samsung Bioepis has started direct commercialisation of Byooviz, a biosimilar to Genentech’s Lucentis (ranibizumab), in ...

Insilico Medicine has entered a multi-year R&D collaboration with Servier, worth up to $888m, to develop and discover new ...